Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.59 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 16/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31020127 | 0.93 | ESR2 (0.69) | ESR2NR1H2GPR119 | |
| SCHEMBL4789776 | 0.93 | ESR2 (0.69) | ESR2NR1H2GPR119 | |
| SCHEMBL18022672 | 0.87 | ESR2 (0.53) | ESR2NR1H2GPR119 | |
| SCHEMBL21753272 | 0.85 | GPR119 (0.59) | ESR2NR1H2GPR119 | |
| SCHEMBL3702146 | 0.83 | ESR2 (0.85) | ESR2NR1H2NPC1RAB9AHDAC6 | |
| SCHEMBL31621565 | 0.82 | ESR2 (0.67) | ESR2NR1H2GPR119 | |
| SCHEMBL31621666 | 0.82 | ESR2 (0.67) | ESR2NR1H2GPR119NPC1RAB9A | |
| SCHEMBL30409191 | 0.82 | ESR2 (0.67) | ESR2NR1H2GPR119 | |
| SCHEMBL4924112 | 0.81 | NR1H2 (0.77) | ESR2NR1H2NPC1RAB9AHDAC6 | |
| SCHEMBL2984097 | 0.81 | ESR2 (0.63) | ESR2NR1H2NPC1RAB9AHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | ASCENEURON SA (CH) | 2023-10-24 | — | — | US | disclosed |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | ASCENEURON SA (CH) | 2023-10-24 | — | — | US | disclosed |
| US-20220380358-A1 | TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-12-01 | — | — | US | disclosed |
| WO-2020039028-A1 | TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380358-A1 | TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS | BACE1, BACE2, BCHE | ESR2 1696/4885NR1H2 856/4885GPR119 340/4885 |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | BACE1, BACE2, BCHE | ESR2 1696/4885NR1H2 856/4885GPR119 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.